The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001233314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/09/2026
Date registered
Help: Date registered
8/10/2026
Date last updated
Help: Date last updated
8/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
8/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Home-based transcranial direct current stimulation for the treatment of chronic low back pain: a randomised controlled trial
Scientific title
Home-based transcranial direct current stimulation for the treatment of chronic low back pain in adults: a randomised controlled trial
Additional trial identifiers [1] 318223 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Chronic Low Back Pain 343280 0
Condition category
Condition code
Musculoskeletal 339398 339398 0 0
Other muscular and skeletal disorders
Neurological 339756 339756 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will be randomly allocated to receive either: i) active home-based transcranial direct current stimulation (tDCS), or ii) sham home-based tDCS. Participants will receive 20 minutes of either active or sham home-based tDCS daily from Monday-Friday for 2-weeks.

The tDCS headpiece will be fitted by the researchers and participants provided with an instructional video (2-minutes) regarding correct headpiece positioning at baseline. The tDCS device will be pre-programmed for both the active and sham conditions and the participant will be blinded to this allocation. During active tDCS, stimulation with a constant current intensity of 2mA will be applied over the motor cortex via a Soterix mini-tDCS Stimulator. The 5×7cm saline-soaked sponge electrodes snap into the custom headpiece, ensuring fail-safe electrode preparation. Participants will simply need to press a button with the headpiece appropriately positioned to receive the pre-programmed intervention and will not be able to modify any settings. Participants will remove the headpiece when the tDCS unit automatically turns off after 20 minutes. Participants will complete their first session in-person after baseline assessment. They will then be supervised by researchers via secure videoconferencing software to provide support during their first home-based sessions. All subsequent sessions will be self-administered at home.

Whilst completing the tDCS sessions, participants will be asked to fill out a diary during and after each session. This diary includes a pre-session checklist (scalp clean/dry, sponges saturated with saline, red-to-red cable and black-to-black cable), and questions regarding start/end time, code entered, contact quality, battery charge at start/end, whether the session was completed, and any sensations felt and the severity of that sensation. Once the tDCS devices are returned to the research team, they will also be checked to ensure each prescribed code was used.

At baseline participants will be asked to complete questionnaires relating to pain intensity, disability, and intervention acceptability/feasibility/appropriateness. Participants will complete the questionnaires relating to pain intensity and disability every week for 8 weeks (totalling nine time-points). Feasibility measures of fidelity, adoption and reach will also be assessed throughout the intervention period. It is expected that these questionnaires will take approximately 15 minutes to complete. Further, it is anticipated that in addition to the 20 minutes of tDCS stimulation, participants will take approximately 5 minutes to set-up/set-down the device. This time is inclusive of putting on the device as well as completing their participant diary.
Intervention code [1] 335124 0
Treatment: Devices
Description of the comparator or control
The sham condition will involve identical procedures, except the pre-programmed sham protocol (which delivers no actual stimulation to the motor cortex) will be employed.
Control group
Placebo

Outcomes
Primary outcome [1] 346602 0
Pain intensity
Timepoint [1] 346602 0
Outcome will be assessed at Baseline (prior to treatment commencement) and at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, and Week 8 post-treatment commencement.
Primary outcome [2] 346707 0
Disability
Timepoint [2] 346707 0
Outcome will be assessed at Baseline (prior to treatment commencement) and at Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7, and Week 8 post-treatment commencement.
Secondary outcome [1] 468328 0
Acceptability
Timepoint [1] 468328 0
Outcome will be assessed at Baseline (prior to treatment commencement) and at Week 2 post-treatment commencement.
Secondary outcome [2] 468329 0
Feasibility
Timepoint [2] 468329 0
Outcome will be assessed at Baseline (prior to treatment commencement) and at Week 2 post-treatment commencement.
Secondary outcome [3] 468330 0
Fidelity
Timepoint [3] 468330 0
Outcome will be assessed Week 1 and Week 2 post-treatment commencement.
Secondary outcome [4] 468331 0
Adoption
Timepoint [4] 468331 0
Cumulative enrolment data will be assessed at the conclusion of the recruitment phase.
Secondary outcome [5] 468332 0
Appropriateness
Timepoint [5] 468332 0
Outcome will be assessed at Baseline (prior to treatment commencement) and at Week 2 post-treatment commencement.
Secondary outcome [6] 468333 0
Reach
Timepoint [6] 468333 0
Cumulative data on reasons for non-participation will be assessed at the conclusion of the recruitment phase.

Eligibility
Key inclusion criteria
Eligible participants will be adults living in the metropolitan area aged 18 years or older with chronic low back pain (CLBP), defined as pain of greater than three months’ duration in the region between the inferior aspect of the 12th ribs and the inferior gluteal folds. Participants will be required to report an average weekly pain intensity of at least 30 mm on a 100 mm online VAS anchored by ‘no pain’ (0 mm) and ‘extreme pain’ (100 mm).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they report greater pain in another body region, have a specific spinal pathology (fracture; malignant, inflammatory or infective diseases of the spine; cauda equina syndrome or widespread neurological disorder), have radicular low back pain, are pregnant, or have any contraindication to tDCS.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
sealed opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD

Funding & Sponsors
Funding source category [1] 322784 0
University
Name [1] 322784 0
Queensland University of Technology
Country [1] 322784 0
Australia
Primary sponsor type
University
Name
Queensland University of Technology
Address
Country
Australia
Secondary sponsor category [1] 325710 0
None
Name [1] 325710 0
Address [1] 325710 0
Country [1] 325710 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321225 0
Queensland University of Technology University Human Research Ethics Committee
Ethics committee address [1] 321225 0
Ethics committee country [1] 321225 0
Australia
Date submitted for ethics approval [1] 321225 0
23/05/2026
Approval date [1] 321225 0
21/09/2026
Ethics approval number [1] 321225 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153066 0
Miss Keeley McNally
Address 153066 0
Queensland University of Technology Q Block (KG-Q Research Facility) – 60 Musk Avenue, Kelvin Grove, Brisbane, Queensland 4059, Australia
Country 153066 0
Australia
Phone 153066 0
+61 432651701
Fax 153066 0
Email 153066 0
Contact person for public queries
Name 153067 0
Keeley McNally
Address 153067 0
Queensland University of Technology Q Block (KG-Q Research Facility) – 60 Musk Avenue, Kelvin Grove, Brisbane, Queensland 4059, Australia
Country 153067 0
Australia
Phone 153067 0
+61 432651701
Fax 153067 0
Email 153067 0
Contact person for scientific queries
Name 153068 0
Keeley McNally
Address 153068 0
Queensland University of Technology Q Block (KG-Q Research Facility) – 60 Musk Avenue, Kelvin Grove, Brisbane, Queensland 4059, Australia
Country 153068 0
Australia
Phone 153068 0
+61 432651701
Fax 153068 0
Email 153068 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
What individual participant data might be shared?
• De-identified individual participant data:
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Upon reasonable request via email ([email protected]) to the Principal Investigator

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.